Journal
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
Volume 21, Issue 2, Pages 155-176Publisher
BEGELL HOUSE INC
DOI: 10.1615/CritRevEukarGeneExpr.v21.i2.50
Keywords
C8-aryl purines; phosphoramidites; Suzuki cross-coupling reaction; therapeutics; modified oligonucleotides synthesis
Funding
- NSF [EPS 0554328, EPS-1003907]
- WVEPSCoR [HEPC. dsr.09013]
- NIH [0491233, P20RR16477]
- NATIONAL CANCER INSTITUTE [R01CA135096] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016477] Funding Source: NIH RePORTER
Ask authors/readers for more resources
C8-Aryl purines, their nucleosides, and phosphoramidites have been synthetic targets for more than 60 years. Interest in these compounds stems from their utility as fluorescent markers, biomarkers, biomolecular probes, and supramolecular building blocks, as well as their uses in therapy and for conformational studies. Until recently, the selective arylation of the C8 position of purines has been a challenging task. Several approaches have been explored, including building them up from a pyrimidine or selective C8 modification of an unsubstituted purine. Neither of these approaches has proven to have broad scope. The discovery that C8-aryl purine nucleosides can be made via the Suzuki cross-coupling reaction has allowed a diverse array of analogs to be prepared and, in turn, the corresponding phosphoramidites. The latter is particularly significant as C8-aryl purine adducts are a major mutation observed from aromatic carcinogens, and ready access to C8-aryl phosporamidites will facilitate the synthesis and study of C8-aryl purine biomarkers and modified oligonucleotides.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available